Extracorporeal membrane oxygenation

Em-tec Announces Release of SonoTT aQuila System

Retrieved on: 
Wednesday, March 27, 2024
Anomaly, Product management, Finning, ECMO, PSG, Blood, HLM, Extracorporeal membrane oxygenation, Yolo Bypass, Documentation, Safety, Medical device

The SonoTT aQuila Flow Measurement System is designed to advance the safety and quality of flow-measurement applications during a variety of medical treatments, such as extracorporeal membrane oxygenation (ECMO), the use of a heart-lung machine (HLM), apheresis, (hemo)dialysis, and distal perfusion.

Key Points: 
  • The SonoTT aQuila Flow Measurement System is designed to advance the safety and quality of flow-measurement applications during a variety of medical treatments, such as extracorporeal membrane oxygenation (ECMO), the use of a heart-lung machine (HLM), apheresis, (hemo)dialysis, and distal perfusion.
  • "We are excited to launch the new SonoTT aQuila System, which represents the next-generation technology that allows us to better serve our existing and new customers and open up strategically important markets," said Christian Steer, Director of Product Management at Em-tec.
  • Stand-alone sensor technology, such as that offered by Em-tec's new SonoTT aQuila System, can be flexibly used for the independent measurement and display of blood flow values, resulting in enhanced safety and quality in a wide variety of treatment methods in which blood flow monitoring is vital.
  • The innovative SonoTT aQuila System was developed at the Finning site in Germany.

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

Retrieved on: 
Thursday, January 25, 2024
ANN, Death, Mortality, Patient, The Lancet, Intubation, Hospital, Intensive care medicine, FCCP, COVID-19 deaths, Internal medicine, Survival, Medicine, ECMO, Critical care, Food, Commitment, Disease, COVID-19, FDA, Therapy, IMV, Extracorporeal membrane oxygenation, Emergency Use Authorization, Physician, Pharmaceutical industry

InflaRx is determined to support broader access to GOHIBIC for eligible patients.

Key Points: 
  • InflaRx is determined to support broader access to GOHIBIC for eligible patients.
  • ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that the Company has launched The InflaRx Commitment Program (Commitment Program).
  • With today´s announcement, we are demonstrating our strong commitment to help make GOHIBIC available for the most affected COVID-19 patients as a potential life-saving therapy.
  • For detailed information about the Commitment Program and to file a claim, please visit this link: The InflaRx Commitment Program .

Human medicines European public assessment report (EPAR): Veklury, remdesivir, Date of authorisation: 03/07/2020, Revision: 23, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
RNA, Medical Subject Headings, Marketing, Liver, INN, Risk, Adolescence, Pneumonia, Extracorporeal membrane oxygenation, COVID 19, International, Mortality, ECMO, Nausea, Language, Ventilation, COVID, COVID-19, European Medicines Agency, SARS-CoV-2, Risk management, Select, Cell, Patient, Safety, IIA, Viral, Medical device

Human medicines European public assessment report (EPAR): Veklury, remdesivir, Date of authorisation: 03/07/2020, Revision: 23, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Veklury, remdesivir, Date of authorisation: 03/07/2020, Revision: 23, Status: Authorised

Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024

Retrieved on: 
Tuesday, December 26, 2023
Annual report, Extracorporeal membrane oxygenation, FDA, ART, Hospital, Health, HYLA, Risk, Blood, Patient, OXY, Hemofiltration, Dialysis, ICU, Medical device

This breakthrough, in achieving 95% accuracy compared to standard blood gas analyzers, brings continuous and real-time blood monitoring capabilities compared to traditional blood gas analyzer systems used in hospitals that typically require intermittent blood draws.

Key Points: 
  • This breakthrough, in achieving 95% accuracy compared to standard blood gas analyzers, brings continuous and real-time blood monitoring capabilities compared to traditional blood gas analyzer systems used in hospitals that typically require intermittent blood draws.
  • This sensor technology is designed to be integrated with the Company's INSPIRA ART100 and was submitted to the FDA in September 2023, with clearance anticipated in the first half of 2024.
  • The HYLA™ Blood Sensor line (the "Blood Sensor") is set to transform intensive care unit (ICU) operations, offering continuous, real-time blood data collection and analysis.
  • This approach has enabled to define the Blood Sensor's disposable materials and methods, with HYLA's planned razor blade business model.

In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil, to Medical Advisory Board

Retrieved on: 
Monday, December 11, 2023
Food and Drug Administration, Inspira Health Network, Food, Rabin Medical Center, Risk, Patient, Extracorporeal membrane oxygenation, OXY, FDA, Annual report, Nursing care plan, Cardiothoracic surgery, Unitary state, Pharmaceutical industry, Medical device

Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board.
  • Dr. Gorfil's expertise are expected to significantly contribute to the deployment of the INSPIRA™ ART100.
  • "My commitment to life support innovation led me to Inspira Technologies," stated Dr. Gorfil.
  • Dagi Ben-Noon, CEO of Inspira Technologies, commented, "Dr. Gorfil's appointment represents a strategic step towards accelerating our technology's time-to-market.

Understanding Survival Factors in Critically Ill Patients on Extracorporeal Membrane Oxygenation

Retrieved on: 
Friday, November 17, 2023
Hospice and palliative medicine, Extracorporeal membrane oxygenation, ECMO, Intensive care unit, Prevalence, Chung-Ang University, Ageing, Risk, ICU, Mortality, Patient, Intensive care medicine, Heart, COVID-19, MAP, Critical care nursing, Survival, Death, Survivor, Professor, Intensive word form, Collaboration, Medical device, Nursing, Pharmaceutical industry

SEOUL, Nov. 17, 2023 /PRNewswire/ -- Extracorporeal membrane oxygenation (ECMO), a widely used life support modality, is associated with a high in-hospital mortality rate. Now, researchers from Chung-Ang University, Korea have assessed the prevalence of ECMO-associated deaths and identified the related risk factors. These findings aim to enhance the management of patients requiring ECMO.

Key Points: 
  • SEOUL, Nov. 17, 2023 /PRNewswire/ -- Extracorporeal membrane oxygenation (ECMO), a widely used life support modality, is associated with a high in-hospital mortality rate.
  • Extracorporeal membrane oxygenation (ECMO) is a vital life support procedure that provides cardiac and respiratory support to critically ill patients.
  • Identifying risk factors for in-hospital mortality and developing standardized nursing practice guidelines for ECMO management may improve survival rates.
  • Title of original paper: Factors associated with 30-day in-hospital mortality in critically ill adult patients receiving extracorporeal membrane oxygenation: A retrospective cohort study

Observational Study Finds That Hyperfine, Inc. Portable MR Brain Imaging System Assists Clinicians in Early Detection of Acute Brain Injury in ECMO Patients

Retrieved on: 
Thursday, November 2, 2023
Health Technology, Health, Neurology, Medical Devices, Hyperfine structure, Stroke, FDA, MRI, Extracorporeal membrane oxygenation, Incidence, Brain damage, Mortality, ABI, Multimedia, CT, Brain, ECMO, Medical imaging, Patient, MD

The study evaluated the feasibility of using portable MR brain imaging for monitoring patients during ECMO use, highlighting its potential advantage in providing early visualization of ischemic stroke compared to computerized tomography (CT) scans.

Key Points: 
  • The study evaluated the feasibility of using portable MR brain imaging for monitoring patients during ECMO use, highlighting its potential advantage in providing early visualization of ischemic stroke compared to computerized tomography (CT) scans.
  • The initial findings of this study demonstrate the feasibility of using portable MR brain imaging with adult ECMO patients.
  • It concludes that the incidence of acute brain injury was high, with ischemic stroke being the most common type of injury.
  • “This may be particularly important when you consider mortality rates due to acute brain injury in ECMO patients and emphasizes the need for early and accurate neuromonitoring.”
    “The study’s findings are very encouraging, especially as they relate to the benefits of using the Swoop® portable brain imaging system for early assessment of acute brain injury in patients being treated with ECMO.

RAJANT WORLD MUSIC BENEFIT FOR CHILDREN’S HOSPITAL OF PHILADELPHIA

Retrieved on: 
Wednesday, September 27, 2023
Sentinel, Extracorporeal membrane oxygenation, CHOP, Maverick, ECMO, Quality of life, Philadelphia (magazine), Community, Fastsigns, Kinetic, Patient, Conditional sentence, Music, Medical device

Malvern, Pennsylvania (USA), Sept. 27, 2023 (GLOBE NEWSWIRE) -- Rajant Corporation , the pioneer of Kinetic Mesh® wireless networks, will host the fourth annual “Rajant World Music Benefit” on behalf of Children’s Hospital of Philadelphia (CHOP).

Key Points: 
  • Malvern, Pennsylvania (USA), Sept. 27, 2023 (GLOBE NEWSWIRE) -- Rajant Corporation , the pioneer of Kinetic Mesh® wireless networks, will host the fourth annual “Rajant World Music Benefit” on behalf of Children’s Hospital of Philadelphia (CHOP).
  • Making this possible are Rajant’s fellow “Rajant World Music Benefit” sponsors.
  • Adds Paul Meyer, Connectronics Managing Director, “The Rajant World Music Benefit is an exemplary cause, and Connectronics is grateful for the opportunity to support the initiative.
  • We applaud the Children’s Hospital of Philadelphia and Rajant for directly impacting the lives of these families in such a positive manner.